Jazz Pharmaceuticals, Inc. Completes Enrollment In First Of Two Phase III Clinical Trials Of Sodium Oxybate To Treat Fibromyalgia
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced completion of enrollment in the first of two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia. “Completion of enrollment in this trial is a key milestone in the JZP-6 program. We expect to report top line results from this trial in the fourth quarter of 2008,” said Samuel Saks, M.D., Chief Executive Officer.
More: continued here